Open AccessDecrease in serum anti‐Müllerian hormone level per puncture with laparoscopic ovarian drilling using ultrasonically activated device
Author(s) -
Ogawa Shuichi,
Atsuki Yusuke,
Shimada Kazuhiko,
Motoyama Mitsuhiro,
Suzuki Tatsuya,
Fujiwara Hiroyuki
Publication year - 2021
Publication title -
reproductive medicine and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.005
H-Index - 22
eISSN - 1447-0578
pISSN - 1445-5781
DOI - 10.1002/rmb2.12405
Subject(s) - medicine , anti müllerian hormone , infertility , laparoscopy , polycystic ovary , body mass index , urology , hormone , ovarian reserve , gynecology , endocrinology , gastroenterology , surgery , pregnancy , insulin , insulin resistance , genetics , biology
Abstract Purpose To determine the contributing factor in infertility treatment with laparoscopic ovarian drilling (LOD) to the decrease in serum anti‐Müllerian hormone (AMH) levels in patients with polycystic ovarian syndrome using an ultrasonically activated device. Methods A retrospective analysis was performed in 60 patients (aged 23–36 years) who received 25–120 punctures in each ovary with LOD treatment from January 2014 to December 2018. Results The mean decrease in serum AMH level per puncture with LOD was 0.07 ± 0.04 ng/ml in all 60 patients and 0.08 ± 0.04 ng/ml in patients with ≥10 ng/ml preoperative serum AMH level, which was significantly higher than in those with <10 ng/ml (0.05 ± 0.02 ng/ml). The mean decrease in serum AMH level per puncture in patients with body mass index (BMI) < 18.5 kg/m 2 (0.10 ± 0.03 ng/ml) was significantly higher than in those with BMI 18.5–25 kg/m 2 (0.07 ± 0.04 ng/ml) and >25 kg/m 2 (0.06 ± 0.02 ng/ml). Conclusions The mean decrease in serum AMH levels per puncture with LOD using an ultrasonically activated device depends on the preoperative serum AMH level and BMI of patients.